Abstract
Treatment with aromatase inhibitors (AIs) or tamoxifen does not increase the risk of Parkinson’s Disease (PD) in women with breast cancer. The insignificant increase in PD associated with AIs on univariate analysis is an age effect, that is, older women are more likely to receive AIs and more likely to develop PD.
Publication types
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Antineoplastic Agents, Hormonal / adverse effects
-
Aromatase Inhibitors / adverse effects
-
Biological Specimen Banks
-
Breast Neoplasms* / chemically induced
-
Breast Neoplasms* / drug therapy
-
Breast Neoplasms* / epidemiology
-
Chemotherapy, Adjuvant
-
Female
-
Humans
-
Parkinson Disease* / drug therapy
-
Parkinson Disease* / epidemiology
-
Tamoxifen / adverse effects
-
United Kingdom / epidemiology
Substances
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Tamoxifen